SPENGA member offer · $50 off with code SPENGA50
SPENGA Powered by Apex Meds Get started
Recovery & repair · Injectable

Wolverine Stack

BPC-157 + TB-500

The two recovery peptides, under one physician's plan.

BPC-157 and TB-500 prescribed together for members whose training is limited by how fast they recover. Evaluated by a licensed Apex MD provider and filled by a licensed U.S. pharmacy.

$350per month · injectable

SPENGA members: $50 off with code SPENGA50

  • Physician prescribed
  • Licensed U.S. pharmacy
  • Ongoing medical support
  • Arrives reconstituted
Apex Meds Wolverine Stack vial in SPENGA green
Form
Subcutaneous injection
Course
A set cycle, then a break
Prescribed by
Licensed Apex MD provider
Contains
BPC-157 and TB-500
What it is

Wolverine Stack, in plain terms

The Wolverine Stack is the common name for BPC-157 and TB-500 used together. The nickname comes from the comic-book character known for healing fast. It is a name, not a promise.

BPC-157 is a 15-amino-acid peptide modelled on a protective protein found in stomach fluid. TB-500 is a short synthetic fragment of thymosin beta-4, a protein present in nearly every human cell and concentrated in platelets and wound fluid.

How it works

What it does in the body

In laboratory and animal work, BPC-157 supports the growth of new blood vessels and the activity of the cells that rebuild tendon. Thymosin beta-4 regulates actin, the scaffolding that lets cells change shape and travel to injured tissue.

The two are paired on the reasoning that they act on different parts of repair. That is a mechanistic rationale. It has not been confirmed in people.

The evidence

What the research shows, and what it doesn’t

Every finding is labelled by the kind of study it came from, with the source linked.

Animal and lab

A 2025 systematic review of BPC-157 in sports medicine found 36 studies. Thirty-five were animal or lab studies, which showed improved healing of muscle, tendon, ligament and bone.

Vasireddi et al., systematic review, 2025
Animal

In rats, full-length thymosin beta-4 sped up skin wound closure, with re-epithelialization up 42% at day four and 61% at day seven.

Malinda et al., J Invest Dermatol, 1999
Early human data

In a small retrospective series of knee-pain patients given BPC-157 by injection into the joint, most reported improvement. There was no control group.

Lee & Padgett, 2021
Animal

The one animal study to compare them directly, in rat Achilles tendon repair, found the combination did not outperform either peptide on its own.

Bicer et al., Joint Diseases and Related Surgery, 2026
Not yet studied

No controlled human trial has tested BPC-157 and TB-500 together, and no human study has used either by subcutaneous injection for athletic recovery.

FDA evaluation of BPC-157, 2026

Published research describes what was observed in a study. It is not a promise of what any product will do for you. Your provider will talk through what is realistic.

What to expect

On the protocol

01

How it's taken

Small injections just under the skin over a set cycle, followed by a break. Your provider sets the dose, the schedule and the length of the cycle. It arrives already reconstituted by the pharmacy, so there is no powder to mix and nothing to measure out.

02

What people report

Patients commonly describe first changes in soreness or mobility within a few weeks. These are patient reports, not trial outcomes, and results are not guaranteed.

03

Keep your care team

Peptides are not a substitute for diagnosis, physical therapy or orthopaedic care. Tell your provider about any injury you are treating.

Safety

Know this before you start

Your provider reviews your full history. Tell them about every medication and condition, including any history of cancer.

Reported side effects

  • Redness, swelling or itching at the injection site
  • Headache
  • Fatigue or lightheadedness
  • Mild nausea
  • Long-term safety has not been studied

Who should not use it

  • Active cancer or any history of cancer without oncologist clearance
  • Pregnancy or breastfeeding
  • Anyone under 18
  • Athletes subject to drug testing
Tested athletes

Not for drug-tested athletes

Both ingredients are prohibited at all times under World Anti-Doping Agency rules. Many collegiate, professional and military programs follow the same list.

FAQ

Wolverine Stack questions, answered

Why is it called the Wolverine Stack?

It is a nickname borrowed from a comic-book character known for fast healing. It is not a medical term and should not be read as a promise.

Is the combination proven to work better than either peptide alone?

No. No human trial has tested the combination, and the one animal study that compared them found no added benefit from combining.

Is it FDA-approved?

No. Neither ingredient is FDA-approved. When prescribed it is a compounded medication, which has not been reviewed by the FDA for safety, effectiveness or quality.

How is it taken?

As small subcutaneous injections over a set cycle, with the schedule set by your provider.

What are the risks?

Injection-site reactions, headache, fatigue and nausea are the most reported. Long-term safety is unknown. Because both peptides support blood vessel growth, people with cancer or a history of cancer should not use them without their oncologist's clearance.

Can competitive athletes use it?

No. Both ingredients are banned at all times under anti-doping rules.

Keep looking

Other peptides for SPENGA members

Exclusive SPENGA member access

Start with Wolverine Stack

Answer a few questions. A licensed Apex MD provider decides whether it is right for you.

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Prescription products require an online evaluation with a licensed medical professional, who will determine whether a prescription is appropriate. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness or quality. Research cited on this site describes published studies and is not a claim about what any product will do for you. Individual results vary.

Sources
  1. Vasireddi et al., systematic review, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/
  2. Malinda et al., J Invest Dermatol, 1999. https://pubmed.ncbi.nlm.nih.gov/10469335/
  3. Lee & Padgett, 2021. https://pubmed.ncbi.nlm.nih.gov/34324435/
  4. Bicer et al., Joint Diseases and Related Surgery, 2026. https://pubmed.ncbi.nlm.nih.gov/42542926/
  5. FDA evaluation of BPC-157, 2026. https://www.fda.gov/media/193343/download